Vanda Announces Positive Results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) Demonstrating the Long-Term Maintenance Effects of Fanapt® (iloperidone) 

WASHINGTON, June 23, 2015 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today presented positive results from the long-term maintenance REPRIEVE (Relapse prevention study in patients with schizophrenia) clinical study at the 2015 American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida. The REPRIEVE study demonstrated the ability of Fanapt® (iloperidone) to prevent relapse or impending relapse in adult patients with schizophrenia as compared to placebo. In the REPRIEVE study, 79.6% of patients treated with Fanapt® remained relapse free compared to 36.6% for placebo-treated patients. Vanda intends to file a supplemental New Drug Application (sNDA) for Fanapt® with the U.S. Food and Drug Administration (FDA) in the second half of 2015 to include the results from the REPRIEVE study in the Fanapt® package insert.

“We are delighted with the results of the REPRIEVE study presented today at the ASCP annual meeting,” said Mihael H. Polymeropoulos, M.D., Vanda’s President and Chief Executive Officer. “We believe these results underscore the potential benefits of Fanapt as a treatment alternative for adult patients living with schizophrenia.”

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.